Gyorgy Bagdy
Overview
Explore the profile of Gyorgy Bagdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
1883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagy T, Baksa D, Petschner P, Gonda X, Gal Z, Juhasz G, et al.
Neuropsychopharmacol Hung
. 2025 Jan;
26(4):197-203.
PMID: 39760673
Background: Major depressive disorder (MDD) is a complex psychiatric condition significantly impacted by environmental stress and inflammation. Previous research suggests that stress-induced alterations in the blood-brain barrier (BBB) may allow...
2.
Gal Z, Torok D, Gonda X, Eszlari N, Anderson I, Deakin B, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39457114
Mounting evidence supports the key role of the disrupted integrity of the blood-brain barrier (BBB) in stress- and inflammation-associated depression. We assumed that variations in genes regulating the expression and...
3.
Eszlari N, Hullam G, Gal Z, Torok D, Nagy T, Millinghoffer A, et al.
Transl Psychiatry
. 2024 Apr;
14(1):182.
PMID: 38589364
Most current approaches to establish subgroups of depressed patients for precision medicine aim to rely on biomarkers that require highly specialized assessment. Our present aim was to stratify participants of...
4.
Pothorszki D, Koncz S, Torok D, Papp N, Bagdy G
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399409
Differences in the pharmacological effects of (S)-ketamine and (R)-ketamine are at the focus of research. Clinical data and our rat studies confirmed the antidepressant effect of (S)- but not (R)-ketamine,...
5.
Kristof Z, Gal Z, Torok D, Eszlari N, Sutori S, Sperlagh B, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38255938
Both early childhood traumatic experiences and current stress increase the risk of suicidal behaviour, in which immune activation might play a role. Previous research suggests an association between mood disorders...
6.
Koncz S, Papp N, Pothorszki D, Bagdy G
Int J Neuropsychopharmacol
. 2023 Aug;
26(9):618-626.
PMID: 37578355
Background: Racemic ketamine consists of two enantiomers, namely (R)-ketamine and (S)-ketamine, with distinguishable pharmacological properties. Both enantiomers have been reported to show rapid antidepressant effects in rodents. Currently, the (S)-enantiomer...
7.
Kristof Z, Gal Z, Torok D, Eszlari N, Sutori S, Erdelyi-Hamza B, et al.
Sci Rep
. 2023 May;
13(1):7757.
PMID: 37173368
Emotional stress is a leading risk factor in the development of neuropsychiatric disorders possibly via immune activation. P2X7 receptors promote neuroinflammation, and research suggests a relationship between chromosome region 12q2431,...
8.
Bruncsics B, Hullam G, Bolgar B, Petschner P, Millinghoffer A, Gecse K, et al.
Sci Rep
. 2023 Mar;
13(1):4976.
PMID: 36973313
Manipulation of intake of serotonin precursor tryptophan has been exploited to rapidly induce and alleviate depression symptoms. While studies show that this latter effect is dependent on genetic vulnerability to...
9.
Vas S, Papp R, Konczol K, Bogathy E, Papp N, Adori C, et al.
J Neurosci
. 2022 Dec;
43(5):846-862.
PMID: 36564184
Stress disorders impair sleep and quality of life; however, their pathomechanisms are unknown. Prolactin-releasing peptide (PrRP) is a stress mediator; we therefore hypothesized that PrRP may be involved in the...
10.
Gal Z, Torok D, Gonda X, Eszlari N, Anderson I, Deakin B, et al.
Int J Neuropsychopharmacol
. 2022 Dec;
26(3):189-197.
PMID: 36472886
Background: Evidence from rodents indicated that after recent stress, reduced expression of tight junction protein claudin-5 may weaken the blood-brain barrier and allow interleukin-6 to induce depressive symptoms. Our aims...